Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)
- (a)
- The time for response evaluation is 20 to 24 weeks in most psoriasis studies, while it is frankly lower (16 weeks) in the 5 AD studies. In contrast, Silverberg et al. [17] suggests that even a period of 52 weeks should be optimal to evaluate a patient as a SR. It would be more accurate to establish a double range of measurement, either by absolute EASI or by relative EASI with two cut-off points: short and medium term, where the super-response maintenance is demonstrated.
- (b)
- For psoriasis, there is only one objective evaluation of effectiveness, using PASI to define a patient as SR. Additional in AD, both NRS pruritus and DLQI scores are contemplated, introducing the concept of (PROs). The goal in psoriasis is achieving absolute PASI = 0, explained by a longer experience and management with the different biological therapeutic approaches, while in AD, we are still in an initial phase, where it seems difficult to call for achieving an absolute EASI = 0.
Funding
Conflicts of Interest
References
- Pereyra-Rodriguez, J.J.; Alcantara-Luna, S.; Domínguez-Cruz, J.; Galán-Gutiérrez, M.; Ruiz-Villaverde, R.; Vilar-Palomo, S.; Armario-Hita, J.C. Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. Life 2021, 11, 927. [Google Scholar] [CrossRef] [PubMed]
- Linares-Gonzalez, L.; Lozano-Lozano, I.; Gutierrez-Rojas, L.; Lozano-Lozano, M.; Rodenas-Herranz, T.; Ruiz-Villaverde, R. Sexual Dysfunction and Atopic Dermatitis: A Systematic Review. Life 2021, 11, 1314. [Google Scholar] [CrossRef] [PubMed]
- Navarro-Triviño, F.J.; Ayén-Rodríguez, Á. Study of Hypersensitivity to Malassezia furfur in Patients with Atopic Dermatitis with Head and Neck Pattern: Is It Useful as a Biomarker and Therapeutic Indicator in These Patients? Life 2022, 12, 299. [Google Scholar] [CrossRef] [PubMed]
- Németh, D.; Temesvári, E.; Holló, P.; Pónyai, G. Preservative Contact Hypersensitivity among Adult Atopic Dermatitis Patients. Life 2022, 12, 715. [Google Scholar] [CrossRef] [PubMed]
- Ayen-Rodríguez, A.; Pereyra-Rodríguez, J.-J.; Navarro-Triviño, F.J.; Alcantara-Luna, S.; Domínguez-Cruz, J.; Galán-Gutiérrez, M.; Vilar-Palomo, S.; Armario-Hita, J.C.; Ruiz-Villaverde, R. Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review. Life 2022, 12, 1159. [Google Scholar] [CrossRef]
- Harvey, E.S.; Langton, D.; Katelaris, C.; Stevens, S.; Farah, C.S.; Gillman, A.; Harrington, J.; Hew, M.; Kritikos, V.; Radhakrishna, N.; et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur. Respir. J. 2020, 55, 1902420. [Google Scholar] [CrossRef] [PubMed]
- Prasad, V.; Vandross, A. Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin. Proc. 2015, 90, 1639–1649. [Google Scholar] [CrossRef] [PubMed]
- Mesquita, C.T.; Peix, A.; de Amorim Fernandes, F.; Giubbini, R.; Karthikeyan, G.; Massardo, T.; Patel, C.; Pabon, L.M.; Jimenez-Heffernan, A.; Alexanderson, E.; et al. Clinical and gated SPECT MPI parameters associated with super-response to cardiac resynchronization therapy. J. Nucl. Cardiol. 2022, 29, 1166–1174. [Google Scholar] [CrossRef] [PubMed]
- Talamonti, M.; D’Adamio, S.; Galluccio, T.; Andreani, M.; Pastorino, R.; Egan, C.G.; Galluzzo, M. High-resolution HLA typing identifies a new ‘super responder’ subgroup of HLA-C* 06:02-positive psoriatic patients: HLA-C* 06:02/HLA-C* 04, in response to ustekinumab. J. Eur. Acad. Dermatol. Venereol. 2019, 33, e364–e367. [Google Scholar] [CrossRef] [PubMed]
- Feldman, S.R.; Merola, J.F.; Pariser, D.M.; Zhang, J.; Zhao, Y.; Mendelsohn, A.M.; Gottlieb, A.B. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. J. Dermatolog. Treat. 2022, 33, 1670–1675. [Google Scholar] [CrossRef] [PubMed]
- Reich, K.; Strober, B.; Langley, R.; Song, M.; Shen, Y.-K.; You, Y.; Foley, P.; Blauvelt, A. 15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials. J. Am. Acad. Dermatol. 2020, 83, AB145. [Google Scholar] [CrossRef]
- Ruiz-Villaverde, R.; Rodriguez-Fernandez-Freire, L.; Armario-Hita, J.C.; Pérez-Gil, A.; Galán-Gutiérrez, M.; Armario-Hita, J.C.; Galán-Gutiérrez, M. Super responders to guselkumab treatment in moderate-to-severe psoriasis: A real clinical practice pilot series. Int. J. Dermatol. 2022, 61, 1029–1033. [Google Scholar] [CrossRef] [PubMed]
- Eyerich, K.; Weisenseel, P.; Pinter, A.; Schäkel, K.; Asadullah, K.; Wegner, S.; Muñoz-Elias, E.J.; Bartz, H.; Taut, F.J.H.; Reich, K. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: Rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 2021, 11, e049822. [Google Scholar] [CrossRef] [PubMed]
- Ariëns, L.F.; van der Schaft, J.; Spekhorst, L.S.; Bakker, D.S.; Romeijn, G.L.; Kouwenhoven, T.A.; Kamsteeg, M.; Voorberg, A.N.; Oosting, A.J.; de Ridder, I.; et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. J. Am. Acad. Dermatol. 2021, 84, 1000–1009. [Google Scholar] [CrossRef] [PubMed]
- Elisabetta Di Leo, M.D. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study. J. Investig. Allergol. Clin. Immunol. 2022, 32, 124–132. [Google Scholar]
- Paller, A.S.; Bansal, A.; Simpson, E.L.; Boguniewicz, M.; Blauvelt, A.; Siegfried, E.C.; Gadkari, A. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am. J. Clin. Dermatol. 2020, 21, 119–131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Silverberg, J.I.; Simpson, E.L.; Boguniewicz, M.; De Bruin-Weller, M.S.; Foley, P.; Kataoka, Y.; Bégo-Le-Bagousse, G.; Chen, Z.; Shumel, B.; Chao, J.; et al. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis. Acta Derm. Venereol. 2021, 101, adv00585. [Google Scholar] [CrossRef] [PubMed]
- Canonica, G.W.; Bourdin, A.; Peters, A.T.; Desrosiers, M.; Bachert, C.; Weidinger, S.; Simpson, E.L.; Daizadeh, N.; Chen, Z.; Kamat, S.; et al. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases. J. Allergy Clin. Immunol. Pract. 2022, 10, 1515–1526. [Google Scholar] [CrossRef] [PubMed]
Author/Year | SR or CMR | Criteria | Week | Absolute Reduction EASI ≤ 7, N°. (%) |
---|---|---|---|---|
Ariens LFM [9] 2020 | SR | EASI 75/peak pruritus NRS 4 points/DLQI 4 points | 16 | 96 (70.6) |
Nettis E [10] 2022 | SR | EASI 75/peak pruritus NRS 4 points/DLQI 4 points | 16 | 399 (73.7) |
Paller AS [11] 2020 | CMR | EASI 50/peak pruritus NRS 3 points/DLQI 6 points | 16 | 28 (33) |
Silverberg J [12] 2021 | CMR | EASI 50/peak pruritus NRS 4 points/DLQI 3 points | 16–52 | nd |
Canonica WG [13] 2022 | CMR | EASI 50/peak pruritus NRS 3 points/DLQI 4 points | 16 | nd |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ruiz-Villaverde, R.; Domínguez-Cruz, J.; Navarro-Triviño, F.J.; Galán-Gutiérrez, M.; Armario-Hita, J.C.; Pereyra-Rodriguez, J.J. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders). Life 2022, 12, 1192. https://doi.org/10.3390/life12081192
Ruiz-Villaverde R, Domínguez-Cruz J, Navarro-Triviño FJ, Galán-Gutiérrez M, Armario-Hita JC, Pereyra-Rodriguez JJ. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders). Life. 2022; 12(8):1192. https://doi.org/10.3390/life12081192
Chicago/Turabian StyleRuiz-Villaverde, Ricardo, Javier Domínguez-Cruz, Francisco J. Navarro-Triviño, Manuel Galán-Gutiérrez, Jose Carlos Armario-Hita, and Jose Juan Pereyra-Rodriguez. 2022. "Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)" Life 12, no. 8: 1192. https://doi.org/10.3390/life12081192